SPDYA
Basic information
Region (hg38): 2:28782517-28850611
Previous symbols: [ "SPDY1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPDYA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 11 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 4 | |||||
Total | 0 | 0 | 13 | 1 | 1 |
Variants in SPDYA
This is a list of pathogenic ClinVar variants found in the SPDYA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-28783650-G-A | Benign (Oct 16, 2018) | |||
2-28783714-G-A | Likely benign (Jun 06, 2019) | |||
2-28783725-G-C | Benign (Oct 01, 2018) | |||
2-28783757-G-GA | Benign (Aug 12, 2019) | |||
2-28783890-C-T | Likely benign (Apr 07, 2023) | |||
2-28783893-C-G | Likely benign (Mar 07, 2023) | |||
2-28783893-C-T | Likely benign (Mar 26, 2023) | |||
2-28783895-T-G | Likely benign (Apr 28, 2022) | |||
2-28783899-A-G | Likely benign (Jul 17, 2021) | |||
2-28783900-T-C | Likely benign (Mar 29, 2023) | |||
2-28783902-T-G | Likely benign (Jul 29, 2022) | |||
2-28783909-T-C | Likely benign (Jul 29, 2023) | |||
2-28783923-G-A | Likely benign (Apr 08, 2022) | |||
2-28783923-G-T | Cardiovascular phenotype | Likely benign (Aug 31, 2021) | ||
2-28783925-A-C | Uncertain significance (Sep 10, 2023) | |||
2-28783930-A-G | Noonan syndrome | Uncertain significance (Feb 03, 2023) | ||
2-28783931-T-A | Noonan syndrome • Noonan syndrome-like disorder with loose anagen hair 2 | Conflicting classifications of pathogenicity (Jan 07, 2022) | ||
2-28783934-A-C | Noonan syndrome-like disorder with loose anagen hair 2 • Cardiovascular phenotype | Pathogenic (Dec 11, 2023) | ||
2-28783934-A-T | Noonan syndrome-like disorder with loose anagen hair 2 | Pathogenic (Sep 08, 2016) | ||
2-28783948-A-G | Uncertain significance (Aug 07, 2022) | |||
2-28783979-G-GT | Uncertain significance (Mar 19, 2023) | |||
2-28783992-G-C | Likely benign (Sep 26, 2023) | |||
2-28783996-TTTAA-T | Likely benign (Oct 13, 2023) | |||
2-28784096-C-T | Likely benign (Oct 24, 2018) | |||
2-28784117-C-T | Likely benign (Mar 17, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SPDYA | protein_coding | protein_coding | ENST00000334056 | 6 | 68095 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.551 | 0.448 | 125705 | 0 | 23 | 125728 | 0.0000915 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.56 | 105 | 161 | 0.653 | 0.00000798 | 2063 |
Missense in Polyphen | 26 | 55.403 | 0.46929 | 708 | ||
Synonymous | 0.568 | 47 | 52.2 | 0.900 | 0.00000246 | 548 |
Loss of Function | 2.92 | 3 | 15.3 | 0.196 | 7.29e-7 | 212 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000224 | 0.000223 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000114 | 0.000109 |
Finnish | 0.0000927 | 0.0000924 |
European (Non-Finnish) | 0.0000721 | 0.0000703 |
Middle Eastern | 0.000114 | 0.000109 |
South Asian | 0.000201 | 0.000196 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Regulates the G1/S phase transition of the cell cycle by binding and activating CDK1 and CDK2 (PubMed:12972555). Contributes to CDK2 activation without promoting CDK2 phosphorylation, by inducing a conformation change of the CDK2 T- loop that obstructs the substrate-binding cleft prior to kinase activation (PubMed:28666995). Mediates cell survival during the DNA damage process through activation of CDK2 (PubMed:12839962). {ECO:0000269|PubMed:11980914, ECO:0000269|PubMed:12839962, ECO:0000269|PubMed:12972555, ECO:0000269|PubMed:28666995}.;
- Pathway
- Oocyte meiosis - Homo sapiens (human);Progesterone-mediated oocyte maturation - Homo sapiens (human)
(Consensus)
Recessive Scores
- pRec
- 0.0839
Intolerance Scores
- loftool
- 0.347
- rvis_EVS
- 0.1
- rvis_percentile_EVS
- 61.28
Haploinsufficiency Scores
- pHI
- 0.0611
- hipred
- Y
- hipred_score
- 0.730
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.812
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Spdya
- Phenotype
- homeostasis/metabolism phenotype; cellular phenotype; endocrine/exocrine gland phenotype; reproductive system phenotype;
Gene ontology
- Biological process
- G1/S transition of mitotic cell cycle;cellular response to DNA damage stimulus;male meiotic nuclear division;multicellular organism development;positive regulation of cell population proliferation;activation of protein kinase activity;positive regulation of cyclin-dependent protein serine/threonine kinase activity;positive regulation of protein kinase activity
- Cellular component
- nucleus;nucleoplasm
- Molecular function
- protein kinase binding;protein kinase activator activity